Results: A total of 185 manuscripts were identified. Investigators reported results of both single and multiple organisms in the same manuscript. A single organism was used in 125 reports, and multiple organisms, ranging from 2 to 9, were used in 60 reports. Positive results were reported in 239 clinical situations and negative results reported in 49 in a total of 288 clinical conclusions drawn by the respective investigators. The studies are tabulated in this review.
P robiotics are live microbial organisms of human origin that are fed in yogurts or capsules to benefit the host. 1 They have been used since the days of Metchnikoff in the 19th Century. 2 Recent use has shown clear benefits in treating certain infectious diseases 3, 4 and inflammatory bowel disease. [4] [5] [6] Claims are made for their benefit in numerous other diseases, 2 but most claims lack repeated positive results.
In this report, we evaluated the literature, and, to our surprise, found many placebo controlled, randomized controlled, and blinded controlled studies reported in peer-reviewed journals. Numerous organisms were used in varying doses and under varying conditions. This manuscript collates this information reported in credible journals since 1980.
METHODS

All human clinical trials performed from 1980 to
August 2004 that have used probiotic therapy were reviewed by searching the PubMed database. 7 The trials were searched by using specific names of currently used organisms and using the term ''probiotic.'' In an attempt to be inclusive, this was done by two search criteria. Our search parameters were limited to type of study (clinical trial), date , language (English), and subject (human). Each article was read and the following information was extrapolated: 1) probiotic species used, 2) condition for which it was used, 3) dose, 4) frequency of dose, 5) vehicle used to administer, and 6) results of the study. All information was compiled into an Excel spreadsheet for further analysis. All studies performed with the use of single species probiotic were separated from those using multiple species. Positive outcomes were determined by either a reduction in symptoms or improvement in clinical disease if a disease state was studied, or alteration in clinical parameter as determined by the author of the paper. A negative or no effect outcome was determined by no reduction in symptoms or no improvement in disease state if a disease state was studied, or no alteration in any clinical parameters, as noted by the author. Some trials used several organisms individually within one report so that the total number of outcomes do not match the total number of referenced articles. In addition, outcomes within one study can be considered both positive and negative when they are analyzed per symptom.
RESULTS
Twenty-six organisms from 9 different genera were used in the 185 studies and are listed in Table 1 . The most commonly used organisms are from the Lactobacillus group, 12 organisms, and 6 organisms from Bifidobacteria. The other organisms were used less commonly. Several products employ the use of the fungi Saccharomyces. The studies in which single organisms are used are recorded in Table 2 , and the studies in which multiple organisms (ranging from 2 to 9) are used are recorded in Table 3 . These tables include probiotic species used, condition under which species were used, dose, frequency, vehicle, result, and corresponding reference. There is great variation in these categories between the studies. The conditions include gastrointestinal disorders, cardiovascular parameters, and immunologic parameters among others. Doses of probiotics range from 5 3 10 5 to 1 3 10 12 colony forming units (CFUs). Vehicles include yogurt, milk and capsules in addition to others. The results of these studies as concluded by the authors are summarized in Table 4 . Of a total of 288 outcomes studied in all the trials reviewed, 239 were positive outcomes such as an improvement in clinical condition or symptoms, 49 were negative outcomes such as a worsening of clinical condition or symptoms or no effect such as no change in condition or symptoms.
DISCUSSION
Probiotic therapy has shown efficacy in a variety of disease states, although widespread use of them has not been fully accepted by the medical community. [1] [2] [3] [4] It is established that alterations of the bacterial flora play a role in many gastrointestinal diseases and pathophysiologic conditions. If it is accepted that an alteration in flora plays a role in a disease state, then by adding back particular species of flora, one could rebalance the natural intestinal environment. Probiotics are used for this purpose in a variety of infections and diseases. [5] [6] [7] We are unaware of any comprehensive analyses of probiotic studies performed as clinical trials. Therefore, this study was done to examine the extent of use of probiotic therapy in all human clinical trials from 1980 to August 2004. From the information gathered in this compilation, one recognizes the extremely varied use of this type of therapy in disease states. Additionally, there are a great number and variety of probiotic species used in the study of the same disease states, as well as multiple organisms used at the same time. The report identified 27 species used since 1980. We think that this report is important because probiotics are being used more often in disease therapy and both clinicians and investigators will find it helpful in their selection of probiotics for use in a particular clinical situation.
Similar to the great variation of species of organisms and disease states are the variation of the doses used. The range of claimed effective doses was from 5 3 10 5 to 1 3 10 12 CFUs and may be administered in a great variety of ways from capsules to yogurt.
The majority of the studies reported a positive outcome on disease and reflect the positive attitude of authors working in this area. We are in the process of analyzing these studies in an attempt to correlate the reported data as it relates to specific conditions, as well as critically evaluating the controls used in the reports and the validity of the outcomes. There are 239 positive outcomes and relatively few negative observations, which indicate the positive nature of most reports, but critical evaluation of this literature is needed.
Many studies were done to assess the affect on intestinal bacterial microflora as well as to assess the survival of these species through gastrointestinal transit in healthy individuals. This basic information is essential to help understand the mechanisms by which probiotics are effectively delivered to the host. The purpose of this compilation is to report the treatment results as indicated by the authors and not to analyze the pathophysiologic mechanisms of probiotic bacteria on the host and neither to make any specific recommendations. The information compiled in this report may be useful for clinicians in their decision of probiotic use, dosage, and type while we await well-defined controlled clinical studies. 
